PDS Biotechnology Corporation Recorded Big Gain

PDS Biotechnology Corporation (PDSB:NASDAQ) shot up at $2.97, representing a gain of 33.2%. The stock got featured on our News Catalysts scanner on Wed 11 Dec 19 at 05:48 PM in the 'PATNERSHIP' category. From Thu 05 Dec 19, the stock recorded 57.14% Up Days and 40.00% Green Days

The share price of the company has been moving sideways in recent weeks.

About PDS Biotechnology Corporation (PDSB:NASDAQ)

Edge Therapeutics Inc operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. Its core objective lies in the development and commercialization of therapies for serious unmet medical conditions, especially neurological disorders in the hospital setting. The company is currently evaluating EG-1962, its lead product candidate, in the Phase 3 NEWTON 2 study in adult patients with aneurysmal subarachnoid hemorrhage (aSAH). Edge uses its trademark platform known as Precisa, which enables the creation of polymer-based therapeutics capable of delivering directly to the site of injury, without affecting other areas of the body resulting in side-effects.